Before you sell to, join or invest in AstralBio, Inc.
MentionFox check on AstralBio, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/astralbio-inc-form-d-24000001
Check AstralBio, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
AstralBio, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-19.
AstralBio, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 19, 2024. The filing reports $957K sold. Its industry group is Biotechnology. It names Patrick Crutcher (Executive Officer, Director), Justin DiMartino (Executive Officer, Director) (SEC Form D, December 19, 2024).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like AstralBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns AstralBio, Inc.
Free to see. No signup.
Get an email when AstralBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when AstralBio, Inc. raises, hires or launches. No email unless you switch it on.
Watch AstralBio, Inc. →Get the full cited report on AstralBio, Inc.
What the filing shows about AstralBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on AstralBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives AstralBio, Inc.'s address as 867 Boylston Street, 5TH Floor #1833, Boston, MA 02116.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
AstralBio, Inc. is a registered filer with the SEC (CIK 2048715) and has filed since 2024-12-19. 1 filing is on record, the latest on 2024-12-19.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
AstralBio, Inc.'s Form D of 2024-12-19 names Patrick Crutcher and Justin DiMartino as its officers, directors or promoters.
Its new offerings report $957K sold across 1 offering, as its own filings state.
Trailing twelve months. 763 filings in Biotechnology, totalled by week.
The Company will use the proceeds from the sale of the shares for product development and other general corporate purposes.
Patrick Crutcher is named as Executive Officer and Director on the Form D that AstralBio, Inc. filed with the SEC on 19 December 2024, one of 2 people that filing names.
Justin DiMartino is named as Executive Officer and Director on the Form D that AstralBio, Inc. filed with the SEC on 19 December 2024, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2024-12-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about AstralBio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on AstralBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AstralBio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist AstralBio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind AstralBio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for AstralBio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/astralbio-inc-form-d-24000001